In a recent paper, Dr Clive Green and Dr Philip Spencer, both of AstraZeneca (a Titian customer), discuss how drug discovery is undergoing a transformation powered by advances that provide more knowledge from biological assays, allow for screening orders of magnitude more molecules and enable smarter selection of compounds.
